Compositions and methods for weight loss in at risk patient populations
AssigneeOrexigen Therapeutics, Inc.
InventorsPreston Klassen, Kristin Taylor
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.
Claims20
A method of treating a subject for overweight or obesity, comprising:
- selecting an overweight or obese subject at increased risk of adverse cardiovascular outcomes that has had type-two diabetes for a period of less than 6 years;
- and
- treating the subject for overweight or obesity by administering to the subject a daily dose of 32 mg of sustained release naltrexone, or a pharmaceutically acceptable salt thereof and 360 mg bupropion, or a pharmaceutically acceptable salt thereof, for a period of at least 12 weeks.
A method of treating a subject for overweight or obesity, comprising:
- selecting an overweight or obese subject at increased risk of adverse cardiovascular outcomes that is a current smoker that does not have type-two diabetes;
- and
- treating the subject for overweight or obesity by administering to the subject a daily dose of 32 mg of sustained release naltrexone and 360 mg bupropion, or a pharmaceutically acceptable salts thereof, for a period of at least 12 weeks.
A method of treating a subject for overweight or obesity, comprising:
- administering to said subject a daily dose of 32 mg of sustained release naltrexone, or a pharmaceutically acceptable salt thereof and 360 mg bupropion, or a pharmaceutically acceptable salt thereof, for a period of at least 12 weeks, wherein said subject is at increased risk of adverse cardiovascular outcomes and has had type-two diabetes for a period of less than 6 years.
A method of treating a subject for overweight or obesity, comprising:
- administering to the subject a daily dose of 32 mg of sustained release naltrexone and 360 mg bupropion, or a pharmaceutically acceptable salts thereof, for a period of at least 12 weeks, wherein said subject is at increased risk of adverse cardiovascular outcomes and is a current smoker that does not have type-two diabetes.
Dependencies are inferred from the claim text.